Volume 19, Issue 10, Pages (June 2017)

Slides:



Advertisements
Similar presentations
Figure 5 ISOX and vorinostat partially restore splicing pattern in DM1 patient-derived fibroblasts. (A) ISOX and vorinostat partially rescue mis-splicing.
Advertisements

Volume 9, Issue 5, Pages (December 2014)
Volume 9, Issue 5, Pages (November 1998)
Volume 98, Issue 3, Pages (August 1999)
Volume 57, Issue 3, Pages (February 2015)
Volume 30, Issue 1, Pages (April 2008)
Volume 27, Issue 22, Pages e5 (November 2017)
Volume 40, Issue 4, Pages (November 2010)
Volume 24, Issue 3, Pages e4 (July 2018)
Volume 8, Issue 6, Pages (September 2014)
AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation  Graeme J. Gowans,
UV-Induced RPA1 Acetylation Promotes Nucleotide Excision Repair
Feng Zhang, Jiazhong Shi, Chunjing Bian, Xiaochun Yu  Cell Reports 
Volume 24, Issue 8, Pages (August 2018)
Volume 22, Issue 12, Pages (March 2018)
The Intracellular Domain of the Frazzled/DCC Receptor Is a Transcription Factor Required for Commissural Axon Guidance  Alexandra Neuhaus-Follini, Greg J.
Patched1 Regulates Hedgehog Signaling at the Primary Cilium
Glucose-Induced β-Catenin Acetylation Enhances Wnt Signaling in Cancer
Volume 27, Issue 3, Pages (March 2015)
Volume 11, Issue 1, Pages (April 2015)
Phospholipid Scramblase 1 Mediates Type I Interferon-Induced Protection against Staphylococcal α-Toxin  Miroslaw Lizak, Timur O. Yarovinsky  Cell Host.
Jungmook Lyu, Vicky Yamamoto, Wange Lu  Developmental Cell 
Volume 6, Issue 6, Pages (March 2014)
Histamine Inhibits the Production of Interferon-induced Protein of 10 kDa in Human Squamous Cell Carcinoma and Melanoma  Naoko Kanda, Shinichi Watanabe 
FOXO3a Is Activated in Response to Hypoxic Stress and Inhibits HIF1-Induced Apoptosis via Regulation of CITED2  Walbert J. Bakker, Isaac S. Harris, Tak.
Cyclooxygenase-2 Inhibitor Enhances Whereas Prostaglandin E2Inhibits the Production of Interferon-Induced Protein of 10 kDa in Epidermoid Carcinoma A431 
Molecular Therapy - Nucleic Acids
Karolin V. Dorn, Casey E. Hughes, Rajat Rohatgi  Developmental Cell 
Ketoconazole Suppresses Prostaglandin E2-Induced Cyclooxygenase-2 Expression in Human Epidermoid Carcinoma A-431 Cells  Naoko Kanda, Dr., Shinichi Watanabe 
All-Trans-Retinoic Acid Induces Interleukin-8 via the Nuclear Factor-κB and p38 Mitogen-Activated Protein Kinase Pathways in Normal Human Keratinocytes 
Volume 9, Issue 5, Pages (November 2017)
Volume 19, Issue 6, Pages (May 2017)
Volume 20, Issue 2, Pages (July 2017)
Volume 20, Issue 13, Pages (September 2017)
Volume 23, Issue 4, Pages (April 2018)
Volume 3, Issue 2, Pages (February 2006)
Kentaro Abe, Masatoshi Takeichi  Neuron 
Volume 24, Issue 4, Pages e5 (April 2017)
Volume 21, Issue 12, Pages (December 2014)
Essential Role of TGF-β Signaling in Glucose-Induced Cell Hypertrophy
Volume 24, Issue 12, Pages e5 (September 2018)
Volume 16, Issue 3, Pages (September 2014)
Resistance of Human Melanoma Cells Against the Death Ligand TRAIL Is Reversed by Ultraviolet-B Radiation via Downregulation of FLIP  Elke Zeise, Michael.
Volume 127, Issue 4, Pages (October 2004)
Control of Centriole Length by CPAP and CP110
Volume 19, Issue 8, Pages (August 2012)
Xin Xie, Tomas Venit, Nizar Drou, Piergiorgio Percipalle
Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
Volume 66, Issue 1, Pages e10 (April 2017)
Human Telomerase RNA Processing and Quality Control
The Membrane-Lytic Peptides K8L9 and Melittin Enter Cancer Cells via Receptor Endocytosis following Subcytotoxic Exposure  Masayuki Kohno, Tomohisa Horibe,
Protein Kinase D Inhibitors Uncouple Phosphorylation from Activity by Promoting Agonist-Dependent Activation Loop Phosphorylation  Maya T. Kunkel, Alexandra C.
Volume 14, Issue 5, Pages (May 2008)
Volume 17, Issue 12, Pages (December 2016)
Centrosome-Associated NDR Kinase Regulates Centrosome Duplication
Fan Yang, Huafeng Zhang, Yide Mei, Mian Wu  Molecular Cell 
Volume 70, Issue 5, Pages (September 2006)
Teemu P. Miettinen, Mikael Björklund  Cell Reports 
Volume 34, Issue 4, Pages (August 2015)
Volume 93, Issue 2, Pages (April 1998)
Volume 26, Issue 12, Pages e5 (March 2019)
Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB
Volume 2, Issue 3, Pages (September 2012)
Suman Paul, Anuj K. Kashyap, Wei Jia, You-Wen He, Brian C. Schaefer 
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
Volume 65, Issue 5, Pages e4 (March 2017)
Volume 19, Issue 6, Pages (May 2017)
Jörg Hartkamp, Brian Carpenter, Stefan G.E. Roberts  Molecular Cell 
Yun-Gui Yang, Tomas Lindahl, Deborah E. Barnes  Cell 
Volume 27, Issue 9, Pages e5 (May 2019)
Presentation transcript:

Volume 19, Issue 10, Pages 2074-2087 (June 2017) Sonic Hedgehog Activates Phospholipase A2 to Enhance Smoothened Ciliary Translocation  Angela M. Arensdorf, Miriam E. Dillard, Jacob M. Menke, Matthew W. Frank, Charles O. Rock, Stacey K. Ogden  Cell Reports  Volume 19, Issue 10, Pages 2074-2087 (June 2017) DOI: 10.1016/j.celrep.2017.05.033 Copyright © 2017 The Author(s) Terms and Conditions

Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 cPLA2 Inhibitors Modulate Shh Signaling (A) Schematic of a phospholipid showing phospholipase hydrolysis sites. (B) Light2 reporter cells were pretreated with PLA2 inhibitors (MAFP [5 μM], GIRI [5 μM], and BEL [5 μM]; orange), the PLC inhibitor NEO (200 μM, pink), or PLD inhibitors (FIPI [40 nM], PLD1i [40 nM], and PLD2i [40 nM]; purple) prior to stimulation with ShhN-conditioned medium. Statistical significance was determined using one-way ANOVA. (C) Light2 cells were pretreated with a cPLA2 inhibitor (GIRI, diamonds) or an iPLA2 inhibitor (BEL, squares) prior to ShhN-conditioned medium treatment. Statistical significance was determined using two-way ANOVA. (D) NIH 3T3 cells were pretreated with GIRI (4 μM) prior to stimulation with ShhN-conditioned medium. Gli1 and Gli3 protein levels were analyzed in nuclear fractions by western blot. The experiment was performed three times. A representative blot is shown. Arrowheads indicate Gli3 activator and repressor species. Lamin C is the nuclear marker. (E) Diagram of Smo ligand binding pockets. (F and G) Light2 cells were pretreated with GIRI (F) or MAFP (G) prior to SAG- (100 nM, squares), 20-OHC- (10 μM, triangle), or ShhN-conditioned medium (circles). Statistical significance was determined using two-way ANOVA. For all experiments involving Light2 cells, Gli-luciferase reporter activity was normalized to the tk-renilla control and expressed relative to the agonist-stimulated control. PL inhibitors were added 2 hr prior to agonist for pretreatment. Assays were repeated a minimum of three times in triplicate, and all data were pooled. ∗∗∗p ≤ 0.0001; ns, p > 0.05. Error bars indicate SEM. Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions

Figure 2 cPLA2 Influences ShhN- but Not SAG-Induced Smo Ciliary Translocation (A–M) NIH 3T3 cells pretreated with MAFP (5 μM) or GIRI (5 μM) were stimulated with ShhN-conditioned medium SAG (100 nM) or cyclopamine (CYCLO, 10 μM) and imaged by immunofluorescence confocal microscopy. The Smo and/or Gli3 signal in primary cilia was quantified by counting ∼100 cells over a minimum of two experiments. For all images, ciliary tips are indicated by arrowheads. (A) Smo ciliary quantification of cells pretreated with MAFP. (B–F) Representative images for each condition: VEH-treated/VEH-stimulated (B), VEH-treated/ShhN-stimulated (C), MAFP-treated/ShhN-stimulated (D), VEH treated/SAG-stimulated (E), MAFP-treated/SAG-stimulated (F). (G and H) Smo (G) and Gli3 (H) ciliary quantification of cells pretreated with GIRI. (I–M) Representative images for each condition: VEH-treated/VEH-stimulated (I), VEH-treated/ShhN-stimulated (J), GIRI-treated/ShhN-stimulated (K), VEH-treated/SAG-stimulated (L), and GIRI-treated/SAG-stimulated (M). (N) Smo ciliary quantification of cells pretreated with MAFP and stimulated with CYCLO. Significance was determined using a two-tailed Student’s t test. (O–Q) Representative images for each condition: VEH-treated/VEH-stimulated (O), VEH-treated/CYCLO-stimulated (P), MAFP-treated/CYCLO-stimulated (Q). The significance indicated in (A), (G), and (H) was calculated based on total cell number analyzed using two-way ANOVA. For all cilia shown, Smo is green, Gli3 is magenta, the ciliary marker acetylated α-tubulin is blue, and the ciliary base marker Cep290-GFP is magenta. ∗∗∗p ≤ 0.0001; ∗p ≤ 0.05; ns, p > 0.05; nt, not tested. Error bars indicate SEM. Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions

Figure 3 PLA2 Is Activated in a Smoothened-Dependent Manner (A) PLA2 Activity Assay Diagram. (B and C) Lysates were prepared from NIH 3T3 or Smo−/− MEFs treated with ShhN-conditioned medium or SAG (100 nM) with or without MAFP (5 μM). Results are represented as fold activity change relative to vehicle. The experiment was repeated four times in duplicate, and all data were pooled. Significance relative to vehicle controls was determined using one-way ANOVA (B) or two-way ANOVA (C). (D and E) The total fatty acid pool in treated and untreated cells was calculated from the sum of individual fatty acids quantified using the d8-20:4 internal standard (D). Absolute levels of 20:4 were determined using mass spectrometry with the d8-20:4 internal standard (E). The experiment was conducted four times, and all data were pooled. Significance was determined using one-way ANOVA. ∗∗∗p ≤ 0.0001; ∗∗p ≤ 0.001; ns, p > 0.05. Error bars indicate SEM. Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions

Figure 4 cPLA2α Contributes to Smo Signaling (A) RNA was harvested from NIH 3T3 cells and analyzed for expression of cPLA2 genes by qRT-PCR. Analysis was performed three times in triplicate, and all results were pooled. (B and B’) Cells were immunostained using an antibody against active phospho-cPLA2α. Images are representative of ∼200 cells analyzed over two independent experiments (B). (B’) shows a Smo and cPLA2α localization overlay with α-TubAc (top) and without (bottom). (C) Western blot of cPLA2α in Pla2g4a wild-type and knockout MEFs using total and phospho-specific antibodies. Tubulin is the loading control. (D) Western blot of cytoplasmic and nuclear extracts from control and cPLA2α knockout MEFs. Loading controls are tubulin (cytoplasmic) and Lamin C (nuclear). The experiment was repeated three times, and a representative blot is shown. (E and F) The total fatty acid pool in treated and untreated cells was calculated from the sum of individual fatty acids quantified using the d8-20:4 internal standard (E). Absolute levels of 20:4 were determined using mass spectrometry with the d8-20:4 internal standard (F). The experiment was performed four times, and all data were pooled. Significance was determined using two-way ANOVA. (G) NIH 3T3 cells were transfected with pCDNA-cPLA2αHA in the absence and presence of ShhN-conditioned medium. Gli1 protein was analyzed by immunoblot. Tubulin and Lamin C are the cytoplasmic and nuclear loading controls, respectively. The experiment was performed twice. A representative blot is shown. (H) NIH 3T3 cells were transfected with pCDNA-cPLA2αHA (yellow) and stimulated with control (VEH) or ShhN-conditioned medium. Cilia were examined for Smo (green) and Gli3 (magenta) ciliary localization. Acetylated α-tubulin is shown in blue. Arrowheads mark the ciliary tips. Because of excessive signal, HA was split from the overlay and is shown below. Approximately 200 cells were analyzed over two independent experiments. Representative cells are shown. ∗∗∗p ≤ 0.0001; ns, p > 0.05; nd, not detected. Error bars indicate SEM. Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions

Figure 5 Smoothened Activates cPLA2α through Gβγ (A) PLA2 activity assays were performed on lysates from NIH 3T3 cells stimulated with ShhN-conditioned medium in the presence or absence of the Gβγ inhibitor GALL (25 μM). Results are shown as fold change in activity relative to vehicle control. The experiment was performed three times in triplicate, and all data were pooled. Significance was determined using one-way ANOVA. (B) Light2 cells were treated with ShhN-conditioned medium or SAG (100 nM) with or without GALL as indicated. Normalized percent reporter activity is expressed relative to the agonist-stimulated condition set to 100%. The experiment was performed three times in triplicate, and all data were pooled. Significance was determined using two-way ANOVA. (C) Cells were treated with ShhN-conditioned medium or SAG (100 nM) with or without GALL (25 μM) as indicated. Smo localization was analyzed in ≥100 cells across two experiments by immunofluorescence confocal microscopy, and ciliary signal intensity was quantified. Significance was calculated based on number of cells using two-way ANOVA. (D–I) Representative images for each condition: VEH-treated/VEH-stimulated (D), VEH-treated/ShhN-stimulated (E), VEH-treated/SAG-stimulated (F), GALL-treated/VEH-stimulated (G), GALL-treated/ShhN-stimulated (H), GALL-treated/SAG-stimulated (I). Primary cilia are marked by acetylated α-tubulin (α-TubAc, blue), and the base is indicated by Cep290-GFP (magenta). Smo is shown in green. ∗p ≤ 0.05; ∗∗∗p ≤ 0.0001; ns, p > 0.05. Error bars indicate SEM. Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions

Figure 6 Arachidonic Acid Binds Smo and Synergizes with 20(S)-OHC (A and A’) Light2 cells were treated with increasing concentrations of arachidonic acid. Normalized baseline reporter activity is shown relative to the vehicle-treated ShhN-stimulated level of reporter activity, set to 100%, shown in (A’) (A). (A’) Light2 reporter cells were stimulated with ShhN-conditioned medium, 20(S)-OHC (10 μM), or SAG (100 nM) plus increasing arachidonic acid. Enhancement is shown relative to the vehicle-treated, Smo agonist-stimulated level of reporter activity set to 100% for each agonist. Significance was determined using two-way ANOVA. (B) Light2 cells were treated with 20(S)-OHC (10 μM) with or without MAFP (5 μM). MAFP-treated cells were treated with arachidonic acid as indicated. The line indicates the baseline 20(S)-OHC-stimulated level, set to 100%. Significance was determined relative to this control using one-way ANOVA. (C) Arachidonic acid was coupled to agarose beads using click chemistry, and beads were incubated with lysate from SmoYFP-expressing cells in the presence of 20(S)-OHC or vehicle. Binding was competed with cold arachidonic acid. The endocannabinoid N-stearoyldopamine (SD) failed to compete Smo from arachidonic acid beads. The experiment was performed twice. A representative blot is shown. (D and D’) Light2 cells were stimulated with 20(S)-OHC (10 μM) and treated with increasing concentrations of cyclopamine and arachidonic acid (D). In (D’), X marks show the calculated IC50 for cyclopamine at each arachidonic acid concentration tested. Each X represents one independent experiment done in triplicate. For all reporter assays, experiments were repeated two or three times in triplicate, and all data were pooled. (E) Binding of fluorescent BODIPY-cyclopamine to Smo was monitored by flow cytometry. The experiment was performed three times. A representative experiment is shown. (F) A model for cPLA2α modulation of Smo signaling. Initiation of Smo signaling by a CRD oxysterol agonist activates cPLA2α, resulting in lysophospholipid (green) and arachidonic acid (orange) production. Arachidonic acid is proposed to target the TM domain of active Smo to enhance ciliary translocation and bolster signal output. Smo activated by the 7TM agonist SAG induces PLA2 but does not require PLA2-generated lipids for optimal ciliary translocation and high-level signaling. ∗p ≤ 0.05; ∗∗∗p ≤ 0.0001; ns, p > 0.05. Error bars indicate SEM. Cell Reports 2017 19, 2074-2087DOI: (10.1016/j.celrep.2017.05.033) Copyright © 2017 The Author(s) Terms and Conditions